Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring

Curr Opin Pharmacol. 2020 Dec:55:iii-vi. doi: 10.1016/j.coph.2020.12.004.

Authors

Joana Torres¹, Paul Declerck²

Affiliations

¹ Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal; Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
² Faculty of Pharmaceutical Sciences, Departement of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.

PMID: 33357460
DOI: 10.1016/j.coph.2020.12.004

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Biological Factors / economics
Biological Factors / therapeutic use*
Biomarkers
Drug Monitoring
Drug Resistance
Gastrointestinal Agents / economics
Gastrointestinal Agents / therapeutic use*
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / economics
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Biological Factors
Biomarkers
Gastrointestinal Agents
Tumor Necrosis Factor-alpha